Sino Biopharmaceutical, a drugmaker listed on the Hong Kong stock exchange, announced Wednesday that its mainland China subsidiary has obtained the rights to sell two respiratory medications developed by British company GSK.
The subsidiary, Chia Tai Tianqing Pharmaceutical (CTTQ), will take on the responsibility of bringing GSK’s triple therapy inhaler Trelegy Ellipta and dual therapy inhaler Anoro Ellipta to the Chinese market.
Anoro Ellipta is designed for the ongoing treatment of chronic obstructive pulmonary disease, commonly known as COPD. Trelegy Ellipta carries approval for the maintenance treatment of both COPD and asthma.
Under the terms of the arrangement, CTTQ will handle the importing, distribution, and promotion of both products throughout mainland China, with any sales revenue expected to be recorded under CTTQ.
The new agreement represents a broadening of the two companies’ working relationship, which had previously been centered on liver disease. It comes on the heels of a deal announced in May, in which CTTQ agreed to support the rollout of a GSK hepatitis B drug candidate in mainland China.
